{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:27:39Z","timestamp":1791559659135,"version":"4.3.4"},"reference-count":69,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T00:00:00Z","timestamp":1489968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for a multitude of reasons including very late diagnosis. This in part is due to the lack of understanding of the biological behavior of PDAC and the ineffective screening for this disease. Significant efforts have been dedicated to finding the appropriate serum and imaging biomarkers to help early detection and predict response to treatment of PDAC. Carbohydrate antigen 19-9 (CA 19-9) has been the most validated serum marker and has the highest positive predictive value as a stand-alone marker. When combined with carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA 125), CA 19-9 can help predict the outcome of patients to surgery and chemotherapy. A slew of novel serum markers including multimarker panels as well as genetic and epigenetic materials have potential for early detection of pancreatic cancer, although these remain to be validated in larger trials. Imaging studies may not correlate with elevated serum markers. Critical features for determining PDAC include the presence of a mass, dilated pancreatic duct, and a duct cut-off sign. Features that are indicative of early metastasis includes neurovascular bundle involvement, duodenal invasion, and greater post contrast enhancement. 18-F-fluorodeoxyglucose (18-FDG) radiotracer uptake and changes following treatment may predict patient overall survival following treatment. Similarly, pretreatment apparent diffusion coefficient (ADC) values may predict prognosis with lower ADC lesions having worse outcome. Although these markers have provided significant improvement in the care of pancreatic cancer patients, further advancements can be made with perhaps better combination of markers or discovery of unique marker(s) to pancreatic cancer.<\/jats:p>","DOI":"10.3390\/ijms18030667","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T11:39:09Z","timestamp":1490009949000},"page":"667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma"],"prefix":"10.3390","volume":"18","author":[{"given":"John C.","family":"Chang","sequence":"first","affiliation":[{"name":"Division of Radiology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madappa","family":"Kundranda","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic cancer","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"key":"ref_3","unstructured":"Tanabe, K.K., and Howell, D.A. (2016). Clinical Manifestations, Diagnosis, and Staging of Exocrine Pancreatic Cancer, UpToDate."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13833","DOI":"10.3748\/wjg.v20.i38.13833","article-title":"Pathology of pancreatic ductal adenocarcinoma: Facts, challenges, and future developments","volume":"20","author":"Esposito","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"326","author":"Jones","year":"2008","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_7","unstructured":"Edge, S., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., and Trotti, A. (2010). AJCC Cancer Staging Manual, Springer. [7th ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.22852","article-title":"Validation of the 6th edition AJCC pancreatic cancer staging system: Report from the national cancer database","volume":"110","author":"Bilimoria","year":"2007","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269641","DOI":"10.1155\/2015\/269641","article-title":"Anatomical, physiological, and molecular imaging of pancreatic cancer: Current clinical use and future implications","volume":"2015","author":"Chang","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2005.19.711","article-title":"Molecular markers of early pancreatic cancer","volume":"23","author":"Goggins","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_11","first-page":"105","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejso.2006.10.004","article-title":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","volume":"33","author":"Goonetilleke","year":"2007","journal-title":"EJSO"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.amjsurg.2005.08.029","article-title":"Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis","volume":"191","author":"Tessler","year":"2006","journal-title":"Am. J. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jamcollsurg.2016.02.009","article-title":"Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A national cancer database study","volume":"223","author":"Bergquist","year":"2016","journal-title":"J. Am. Coll. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1007\/s00330-014-3262-2","article-title":"Elevated serum CA 19-9 at screening tests: Underlying conditions and role of abdominopelvic CT","volume":"24","author":"Kim","year":"2014","journal-title":"Eur. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1440-1746.2004.03219.x","article-title":"Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population","volume":"19","author":"Kim","year":"2004","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00006676-199411000-00005","article-title":"CA 19-9 as a screening and diagnostic tool in symptomatic patients: The Japanese experience","volume":"9","author":"Satake","year":"1994","journal-title":"Pancreas"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jso.23812","article-title":"Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma","volume":"111","author":"Brown","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ijsu.2013.10.005","article-title":"Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas\u2014A retrospective tumor marker prognostic study","volume":"11","author":"Distler","year":"2013","journal-title":"Int. J. Surg."},{"key":"ref_20","first-page":"328","article-title":"Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer","volume":"3","author":"Wu","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.pan.2016.05.007","article-title":"Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study","volume":"16","author":"Imaoka","year":"2016","journal-title":"Pancreatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00432-012-1371-3","article-title":"Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy","volume":"139","author":"Haas","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00280-014-2450-8","article-title":"Serum levels of LDH, CEA, and CA 19\u201309 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy","volume":"73","author":"Tas","year":"2014","journal-title":"Cancer Chemother. Pharacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jcla.20395","article-title":"Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis","volume":"24","author":"Mroczko","year":"2010","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4161\/cc.6.16.4549","article-title":"Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications, and aberrant microRNA expression","volume":"6","author":"Kovalchuk","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pedersen, K.S, Bamlet, W.R., Oberg, A.L., de Andrade, M., Matsumoto, M.E., Tang, H., Thibodeau, S.N., and Wang, L. (2011). Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018223"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dauksa, A., Gulbinas, A., Barauskas, G., Pundzius, J., Oldenburg, J., and El-Maarri, O. (2012). Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: A pilot study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037509"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13148-015-0139-4","article-title":"Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer","volume":"7","author":"Bauden","year":"2015","journal-title":"Clin. Epigenet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/14712598.2015.1029914","article-title":"Malignant potential in pancreatic neoplasm: New insights provided by circulating miR0223 in plasma","volume":"15","author":"Komatsu","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cncr.29364","article-title":"Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer","volume":"121","author":"Kinugasa","year":"2015","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1078-0432.CCR-10-0248","article-title":"Serum biomarker panels for the detection of pancreatic cancer","volume":"17","author":"Brand","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-5876-7-105","article-title":"Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis","volume":"7","author":"Chang","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nolen, B.M., Brand, R.E., Prosser, D., Velikokhatnaya, L., Allen, P.J., Zeh, H.J., Grizzle, W.E., Lomakin, A., and Lokshin, A.E. (2014). Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094928"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.7314\/APJCP.2015.16.15.6569","article-title":"Applicative value of serum CA 19-9, CEA, CA 125 and CA 242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy","volume":"16","author":"Gu","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1007\/s11033-010-0632-y","article-title":"The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro","volume":"38","author":"Zhang","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000084339","article-title":"Nucleosomes in pancreatic cancer patients during radiochemotherapy","volume":"26","author":"Kremer","year":"2005","journal-title":"Tumor Biol."},{"key":"ref_37","first-page":"2619","article-title":"Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy","volume":"133","author":"Wittwer","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1200\/JCO.2009.24.0317","article-title":"MicroRNAs in cancer: Small molecules with a huge impact","volume":"27","author":"Iorio","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jama.2013.284664","article-title":"MicroRNA biomarkers in whole blood for detection of pancreatic cancer","volume":"311","author":"Schultz","year":"2014","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/jco.2015.33.3_suppl.309","article-title":"Genomic change index (GCI) and liquid biopsies in predicting and monitoring reponse to therapy in advanced pancreatic ductal adenocarcinoma (PDAC)","volume":"33","author":"Kundranda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_41","first-page":"11683","article-title":"Tumor markers CA19-9, CA 242 and CEA in the diagnosis of pancretic cancer: A meta-analysis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pan.2014.07.010","article-title":"Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA 19-9 levels","volume":"14","author":"Chang","year":"2014","journal-title":"Pancreatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3346\/jkms.2015.30.3.259","article-title":"Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma","volume":"30","author":"Kim","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/jclinpath-2014-202451","article-title":"Combination of tumour marker CEA and CA 19-9 improves the prognostic prediction in patients with pancreatic cancer","volume":"68","author":"Reitz","year":"2015","journal-title":"J. Clin. Path."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/ijc.29242","article-title":"A preoperative serum signature of CEA+\/CA125+\/CA19-9>=1000 U\/mL indicates poor outcome to pancreatectomy for pancreatic cancer","volume":"136","author":"Liu","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1179\/joc.2009.21.6.673","article-title":"CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: A retrospective analysis","volume":"21","author":"Tsavaris","year":"2009","journal-title":"J. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2214\/ajr.182.4.1820897","article-title":"Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: Retrospective review of CT scans obtained before diagnosis","volume":"182","author":"Gangi","year":"2004","journal-title":"Am. J. Roentgenol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1007\/s00330-009-1422-6","article-title":"Indicative findings of pancreatic cacner in prediagnostic CT","volume":"19","author":"Ahn","year":"2009","journal-title":"Eur. Radiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.gie.2008.10.030","article-title":"EUS\/EUSFNA for suspected pancreatic cancer: Influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics","volume":"70","author":"Krishna","year":"2009","journal-title":"Gastrointest. Endosc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11605-011-1812-3","article-title":"Small and potentially resectable focal pancreatic lesions noted on CT\/MRI scans in nonjuaundiced patients: Likelihood of neoplasia and utility of EUS","volume":"16","author":"Krishna","year":"2012","journal-title":"J. Gastrointest. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1148\/radiol.2015141020","article-title":"Combining in vitro diagnostics with in vivo imaging for earlier detection of pancreatic ductal adenocarcinoma: Challenges and solutions","volume":"277","author":"Laeseke","year":"2015","journal-title":"Radiology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2016152790","article-title":"Preoperative multidetector CT diagnosis of extrapancreatic perineural or duodenal invasion is associated with reduced postoperative survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: Preliminary experience and implications for patient care","volume":"283","author":"Chang","year":"2016","journal-title":"Radiology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1172\/JCI73455","article-title":"Transport properties of pancreatic cancer describe gemcitabine delivery and response","volume":"124","author":"Koay","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3748\/wjg.15.3114","article-title":"Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: Correlation with angiogenesis and fibrosis","volume":"15","author":"Hattori","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3748\/wjg.v9.i9.2100","article-title":"Correlation of CT enhancement, tumor angiogenesis and pathologic grading of pancreatic carcinoma","volume":"9","author":"Wang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ejrad.2013.12.016","article-title":"Contrast-enhanced CT and diffusion-weighted MR imaging: Performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma","volume":"83","author":"Fukukura","year":"2014","journal-title":"Eur. J. Radiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pan.2016.10.008","article-title":"Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer","volume":"17","author":"Kim","year":"2017","journal-title":"Pancreatitis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2664","DOI":"10.1097\/MD.0000000000002664","article-title":"CT imaging biomarkers predict clinical outcomes after pancreatic cancer surgery","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canlet.2015.02.014","article-title":"Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer","volume":"360","author":"Shi","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/MPA.0000000000000580","article-title":"Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma","volume":"45","author":"Abbott","year":"2016","journal-title":"Pancreas"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Chikamoto, A., Inoue, R., Komohara, Y., Sakamaki, K., Hashimoto, D., Shiraishi, S., Takamori, H., Yamashita, Y.-I., Yoshida, N., and Yamanaka, T. (2017). Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. Ann. Surg. Oncol.","DOI":"10.1245\/s10434-017-5799-1"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/RLU.0000000000001098","article-title":"Metabolic activity by 18F-FDG-PET\/CT is prognostic for stage I and II pancreatic cancer","volume":"41","author":"Pimiento","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_64","first-page":"3117","article-title":"Standardized uptake value on positron emission tomography\/computed tomography predicts prognosis in patients with locally advanced pancreatic cancer","volume":"40","author":"Wang","year":"2015","journal-title":"Abdom. Radiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.mcg.0000225672.68852.05","article-title":"The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer","volume":"40","author":"Bang","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/COC.0b013e3181a76a0b","article-title":"Using 18F Fluorodeoxyglucose positron emission tomography (FDG PET) to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer","volume":"33","author":"Choi","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00000658-199905000-00016","article-title":"18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer","volume":"229","author":"Rose","year":"1999","journal-title":"Ann. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1259\/bjr\/43911400","article-title":"Advanced pancreatic cancer: The use of the apparent diffusion coefficient to predict response to chemotherapy","volume":"82","author":"Niwa","year":"2009","journal-title":"Br. J. Radiol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sun, X., Yang, L., Yan, X., Sun, Y., Zhao, D., Ji, Y., Wang, K., Chen, X.-D., and Shen, B. (2016). DCE-MRI-derived parameters in evaluating abraxane-induced early vascular response and the effectiveness of its synergistic interaction with cisplatin. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162601"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/3\/667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:30:49Z","timestamp":1760207449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/3\/667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"alternative-id":["ijms18030667"],"URL":"https:\/\/doi.org\/10.3390\/ijms18030667","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]}}}